• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Alkylating Agent
    12 Drugs classified under this drug class

    All the Drug Class Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    not in the basket chart

    Alkylating Agent.
    fetotal of 150-200 mg. Child: Not more
    than 0.06 mg/kg bdy. wt. dly.
    Multiple myeloma, seminoma of testes
    and other malign. conds.
    AMPS: 1.8 ml of acid alcohol solv., 9 ml
    of diluent x 100 mg. (Hosp. only). I.V: 1
    mg/kg bdy. wt. repeat. in 8 wks.
    accord. to response.
    Reg. perfus. for malign. melanoma and
    other malign.
    C/I: Neutrophil count of less than 1,500/
    ml, concurrent radio or chemotherapy,
    low platelet count.

    partial basket chart

    Alkylating Agent. Busulfan 60 mg / 10 ml.
    VIALS (sol. for inject.): 1. Every 6 hrs. for
    4 consec. days for total of 16 doses.
    In comb. with other chemother. agents
    and/or radiother. as cond. ther. prior to
    hematopoietic progenitor cell transplant.
    C/I: Hypersens.

    Calciumfolinat “Ebewe” 10 mg/ml
    not in the basket chart
    Calciumfolinat “Ebewe” 10 mg/ml

    Alkylating Agent. Calcium Folinate 10 mg/ml.
    VIALS (sol. for inj.): 1 x 100 mg/10 ml, 200 mg/20 ml, 500 mg/50 ml, 1000 mg/100 ml.
    I.V./I.M. only. If use I.V: No more than
    160 mg/min, diluted with 0.9% sod.
    chlor. sol. or 5% glucose sol. See lit.
    To diminish the toxic. and counteract the
    action of folic acid antagonists in
    cytotoxic ther. As Leucovorin-Fluorouracil
    chemotherapy comb. for cancer tmt.
    C/I: Hypersens., pernicious anem., other
    anem. due to B12 defic.

    Dacarbazine Medac
    partial basket chart
    Dacarbazine Medac

    Alkylating Agent. Dacarbazine (as Citrate) 200, 500, 1000 mg/vial.
    SINGLE DOSE VIALS (Pwdr. for sol. for
    inject./infus.): 1, 10 x 200 mg; (Pwdr. for
    soln for infus.): 1, 10 x 500 mg, 1,000 mg.
    Malign. melanoma: (as single agent):
    200-250 mg/m2 bdy surface area/day)
    I.V. for 5 days every 3 wks. Alt: Shortterm
    infus. (over 15-30 mins). Also
    possible: I.V. 850 mg/m2 on day 1, then
    once every 3 wks. Hodgkin’s dis: 375
    mg/m2 I.V. every 15 days in comb. with
    doxorubicin, bleomycin and
    vinblastine. See lit.
    Malign. melanoma, Hodgkin’s dis.
    C/I: Hypersens., pregn., lact., leucopen.,
    and/or thrombocytopen., severe liver/
    kidney dis.

    partial basket chart

    Alkylating Agent. Dacarbazine 200 mg/vial.
    VIALS (pwdr. for reconstit.): 1 x 200 mg +
    19.7 ml water. I.V. inject.,/infus.
    Monother: 4-5 day cycles of 150-250
    mg/m² bdy surface/day. May repeat
    every 21 days. Alt. tmt: 2.0-4.5 mg/kg/
    day for 1-10 days. Can repeat every 28 days. Inject over ±1 min/infus. over
    15-30 mins. If necess. may be given I.A.
    Comb. chemother: 4-5 day cycles of
    100 mg/m²/day with 21 day intervals
    start. from last day tmt.
    Metastat. malign. melanoma, Hodgkin’s
    dis. as 2nd line ther. when used in comb.
    with other agents.
    C/I: Hypersens., ren. insuffic., bone
    marrow defic., pregn., lact.

    not in the basket chart

    Alkylating Agent. Bendamustine Hydrochloride 25 mg, 100 mg.
    VIAL (pwdr. for concentrate. for sol. for infus.): 5x25, 100 mg. Monother. for chron. lymphoc. leuk.: 100 mg/m² bdy. surf. area bendamustine HCl on 1st and 2nd day; every 4 wks. up to 6 times.
    Monother. for indolent non-Hodgkin's lymphoma. refract. to rituximab: 120 mg/m² bdy. surf. area bendamustine HCl on on 1st and 2nd day; every 3 wks. for at least 6 times.
    Follic. non-Hodgkin’s lymphom.: Comb. with rituximab: The dose is 90 mg/m² bdy. surf. area Demustin I.V. on 1st and 2nd day plus 375 mg/m² rituximab on 1st day; repetit. every 4 wks.
    1st-line tmt. of chron. lymphoc. leuk. (Binet stage B/C) in pts. for whom fludarabine comb. chemother. is not appropr..
    Indolent non-Hodgkin's lymphoma. as monother. in pts., who have progres. during or within 6 mnths. follow. tmt. with rituximab or a rituximab contain. regimen.
    Follicular non-Hodgkin’s lymphom. as 1st line tmt. in comb. with rituximab.
    C/I: Hypersens. Lact. Sev. hep. impair. (serum bilirub. > 3.0 mg/dl). Jaundice. Sev. bone marrow suppres. and severe blood count alterat. (leukocyte and/or platelet values dropped to < 3,000/μl or < 75,000/μl, respectively). Major surg. less than 30 days before start of tmt. Infec., espec. involv. leukocytopenia. Yellow fever vaccin.